Company / Cash & Equivalents
Indivior Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$195.0M
FY2025
5-year range
$195.0M / $319.0M
FY2023-FY2025
Trend
-38.9%
vs FY2024
Sector context
#89 of 207
Health Care
What the data says
At $195M, Indivior's cash & equivalents ranks #89 of 207 in the Health Care sector. Declined from $316M to $195M over the past 2 years.
Based on SEC 10-K filings.
$195M in FY2025.
Declined from $316M to $195M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#89 of 207 in Health CareTop 43% of 207This company $195.0M Sector average $669.5M
▼
-70.9% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 38.9% year-over-year.
- Ranks #89 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $195.0M | -38.9% |
| FY2024 | $319.0M | +0.9% |
| FY2023 | $316.0M | - |
| FY2022 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026